Published in Pediatr Surg Int on December 29, 2012
Integrative omics reveals MYCN as a global suppressor of cellular signalling and enables network-based therapeutic target discovery in neuroblastoma. Oncotarget (2015) 0.81
The role of intracellular calcium for the development and treatment of neuroblastoma. Cancers (Basel) (2015) 0.80
Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma. Cancer Biol Ther (2015) 0.79
MicroRNAs in pediatric central nervous system embryonal neoplasms: the known unknown. J Hematol Oncol (2015) 0.77
miR-506 suppresses neuroblastoma metastasis by targeting ROCK1. Oncol Lett (2016) 0.75
Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance. Genome Med (2017) 0.75
Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma. Oncotarget (2016) 0.75
MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma. Cancer Cell Int (2017) 0.75
Promoter hypermethylation as a mechanism for Lamin A/C silencing in a subset of neuroblastoma cells. PLoS One (2017) 0.75
Induced pluripotent stem cell lines derived from human somatic cells. Science (2007) 71.50
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
c-Myc-regulated microRNAs modulate E2F1 expression. Nature (2005) 31.81
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell (2007) 30.22
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Ultraconserved elements in the human genome. Science (2004) 17.14
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58
Selective blockade of microRNA processing by Lin28. Science (2008) 14.39
Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet (1996) 12.96
The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA. Cell (1997) 12.87
Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 10.88
A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res (2005) 10.46
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64
The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell (2007) 7.99
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med (1985) 7.79
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol (2008) 7.35
p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol (2007) 6.87
Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA (2008) 6.86
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol (2008) 6.66
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene (2007) 6.55
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell (2009) 5.99
Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev (2005) 5.22
p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A (2009) 5.05
Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J (1997) 4.99
H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell (2003) 4.94
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature (2012) 4.53
MicroRNA-125b is a novel negative regulator of p53. Genes Dev (2009) 4.43
Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat Struct Mol Biol (2009) 4.41
International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol (1988) 4.35
Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol (2006) 4.35
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med (2008) 3.80
The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells (2004) 3.78
Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res (2007) 3.74
N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev (2002) 3.71
Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One (2008) 3.68
p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res (2008) 3.58
Posttranscriptional regulation of miRNAs harboring conserved terminal loops. Mol Cell (2008) 3.23
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol (2009) 3.07
MicroRNAs show a wide diversity of expression profiles in the developing and mature central nervous system. Genome Biol (2007) 3.05
Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med (1999) 3.03
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell (2011) 2.99
Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res (2008) 2.86
Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett (2008) 2.85
The MYCN oncogene is a direct target of miR-34a. Oncogene (2008) 2.80
LIN-28 and the poly(U) polymerase PUP-2 regulate let-7 microRNA processing in Caenorhabditis elegans. Nat Struct Mol Biol (2009) 2.79
Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst (2006) 2.79
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res (2008) 2.77
MYCN regulates oncogenic MicroRNAs in neuroblastoma. Int J Cancer (2008) 2.76
Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer (1995) 2.65
Identification of let-7-regulated oncofetal genes. Cancer Res (2008) 2.56
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet (2009) 2.47
P53 mRNA controls p53 activity by managing Mdm2 functions. Nat Cell Biol (2008) 2.43
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res (2006) 2.42
Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci (2008) 2.39
The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma. Mol Cell (2010) 2.38
Features of mammalian microRNA promoters emerge from polymerase II chromatin immunoprecipitation data. PLoS One (2009) 2.29
Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci U S A (1989) 2.25
Cytogenetic features of human neuroblastomas and cell lines. Cancer Res (1981) 2.21
Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature (2010) 2.21
The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci U S A (2005) 2.19
MicroRNA-125b promotes neuronal differentiation in human cells by repressing multiple targets. Mol Cell Biol (2009) 2.08
Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. J Natl Cancer Inst (2004) 2.08
LIN28B promotes colon cancer progression and metastasis. Cancer Res (2011) 2.05
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96
Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell (2005) 1.94
High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A (2010) 1.92
The steroid receptor RNA activator is the first functional RNA encoding a protein. FEBS Lett (2004) 1.92
MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. Oncogene (2009) 1.90
High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J (2008) 1.83
Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res (2010) 1.81
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res (2011) 1.80
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene (1999) 1.79
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res (2009) 1.74
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet (2012) 1.74
MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis (2010) 1.73
MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer (2010) 1.72
Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One (2007) 1.72
CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst (2008) 1.71
The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci U S A (2007) 1.68
High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res (2006) 1.68
Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet (2004) 1.66
CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene (2003) 1.65
Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet (2011) 1.57
Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One (2009) 1.55
Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer (2005) 7.53
Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res (2007) 3.74
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96
Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat Med (2012) 1.92
A 360-kb interchromosomal duplication of the human HYDIN locus. Genomics (2006) 1.91
Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma. Clin Cancer Res (2010) 1.81
MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer (2010) 1.72
Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. PLoS One (2009) 1.55
miRNA Expression profile after status epilepticus and hippocampal neuroprotection by targeting miR-132. Am J Pathol (2011) 1.52
Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. Genome Biol (2006) 1.44
The sequence and analysis of duplication-rich human chromosome 16. Nature (2004) 1.38
miR-126 is downregulated in cystic fibrosis airway epithelial cells and regulates TOM1 expression. J Immunol (2010) 1.38
ArrayCGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer (2007) 1.28
MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway. Carcinogenesis (2012) 1.27
MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer (2011) 1.25
Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis (2005) 1.17
Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PLoS One (2009) 1.15
Differential DNA methylation patterns define status epilepticus and epileptic tolerance. J Neurosci (2012) 1.12
Therapeutic targeting of miRNAs in neuroblastoma. Expert Opin Ther Targets (2010) 1.11
MicroRNA-542-5p as a novel tumor suppressor in neuroblastoma. Cancer Lett (2011) 1.11
Reduced mature microRNA levels in association with dicer loss in human temporal lobe epilepsy with hippocampal sclerosis. PLoS One (2012) 1.10
MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res (2010) 1.09
Expression profiling the microRNA response to epileptic preconditioning identifies miR-184 as a modulator of seizure-induced neuronal death. Exp Neurol (2012) 1.07
Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One (2012) 1.06
MicroRNA-497 increases apoptosis in MYCN amplified neuroblastoma cells by targeting the key cell cycle regulator WEE1. Mol Cancer (2013) 1.05
miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res (2011) 1.03
Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers. Genome Biol (2012) 1.02
MicroRNA-184-mediated inhibition of tumour growth in an orthotopic murine model of neuroblastoma. Anticancer Res (2010) 1.01
Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer (2011) 0.98
MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. Int J Cancer (2013) 0.92
Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis. Mol Carcinog (2010) 0.91
Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol Cancer (2012) 0.91
Primary desmoplastic small round cell tumor of bone: report of a case with cytogenetic confirmation. Cancer Genet Cytogenet (2005) 0.91
High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene. Cancer Genet Cytogenet (2007) 0.89
Management of Congenital Tracheal Stenosis. Pediatrics (2015) 0.88
Metastasis suppressor microRNA-335 targets the formin family of actin nucleators. PLoS One (2013) 0.87
Functional analysis of human T lymphotropic virus type 2 Tax proteins. Retrovirology (2006) 0.87
Discovery and visualization of miRNA-mRNA functional modules within integrated data using bicluster analysis. Nucleic Acids Res (2013) 0.86
miRNA expression profiling of the murine TH-MYCN neuroblastoma model reveals similarities with human tumors and identifies novel candidate miRNAs. PLoS One (2011) 0.84
Aberrant splicing of the PTPRD gene mimics microdeletions identified at this locus in neuroblastomas. Genes Chromosomes Cancer (2008) 0.84
Expressional alterations in functional ultra-conserved non-coding RNAs in response to all-trans retinoic acid--induced differentiation in neuroblastoma cells. BMC Cancer (2013) 0.84
Recurrent genomic imbalances in primary effusion lymphomas. Cancer Genet Cytogenet (2006) 0.83
Robotic surgery in otolaryngology and head and neck surgery: a review. Minim Invasive Surg (2012) 0.82
Co-localization of the oncogenic transcription factor MYCN and the DNA methyl binding protein MeCP2 at genomic sites in neuroblastoma. PLoS One (2011) 0.82
New insights into the genetics of neuroblastoma. Mol Diagn Ther (2013) 0.82
Loss of chromosome 1p/19q in oligodendroglial tumors: refinement of chromosomal critical regions and evaluation of internexin immunostaining as a surrogate marker. J Neuropathol Exp Neurol (2011) 0.80
ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours. Mol Cancer (2013) 0.78
Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma. Pediatr Blood Cancer (2014) 0.77
Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f. Int J Cancer (2014) 0.77
Investigating gene promoter methylation in a mouse model of status epilepticus. Methods Mol Biol (2013) 0.77
Targeted genetic modification of cell lines for recombinant protein production. Cytotechnology (2007) 0.75
Malignant refractory epilepsy in identical twins mosaic for a supernumerary ring chromosome 19. Epilepsia (2004) 0.75
Dysmorphic features and learning disability in an adult male with pure partial trisomy 17q24-q25 due to a terminal duplication. Am J Med Genet (2002) 0.75